Alzheimer disease and associated disorders · 2025
Alzheimer Disease Patients Who Survived COVID-19 Have Rapid Disease Progression and a Higher Risk of Death at 5-year Follow-up: A Retrospective Cohort Study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ursi Giulia Zaparoli, da Silva Mateus Ribeiro, Nakakogue Lindsey Mitie, Fernandes Karen Barros Parron, Bignardi Paulo Roberto
Аннотация
PURPOSE: Alzheimer disease (AD) is the most common neurodegenerative disorder, affecting millions worldwide. COVID-19 has increased the risk of acute complications and death for patients with AD, but the long-term effects on survivors have been little studied. Thus, given the potential role of SARS-CoV-2 in accelerating cognitive decline, this study aimed to assess the effect of COVID-19 on functional deterioration, AD progression, and mortality in these patients.
METHODS: This retrospective cohort study examined medical records of patients with mild to moderate AD treated at a public dementia clinic in southern Brazil between March 2020 and March 2025. Sociodemographic and clinical data were extracted, including COVID-19 status confirmed by molecular testing. AD progression was assessed using the Mini-Mental State Examination (MMSE) and the Katz Index. Multivariate statistical analyses were conducted to identify associations between COVID-19 infection and disease progression. Survival was described by Kaplan-Meier test and analyzed by Cox regression.
RESULTS: A total of 105 individuals with DA were included, of whom 28 (26.7%) were COVID-19 survivors during the follow-up period. COVID-19 patients showed rapid AD progression compared with the control group (OR 4.76; 95% CI: 1.04-21.7; P = 0.044). Likewise, SARS-CoV-2 infection decreased patients' functionality, as indicated by the Katz index ( P =0.001). Functional impairment was observed in both mild and hospitalized cases of COVID-19. Hospitalized patients during COVID-19 demonstrated lower survival rates at the 5-year follow-up.
CONCLUSION: These findings suggest that SARS-CoV-2 infection may accelerate AD progression and reduce survival, particularly in cases requiring hospitalization. Future multicenter studies with large sample sizes are needed to confirm these findings.
METHODS: This retrospective cohort study examined medical records of patients with mild to moderate AD treated at a public dementia clinic in southern Brazil between March 2020 and March 2025. Sociodemographic and clinical data were extracted, including COVID-19 status confirmed by molecular testing. AD progression was assessed using the Mini-Mental State Examination (MMSE) and the Katz Index. Multivariate statistical analyses were conducted to identify associations between COVID-19 infection and disease progression. Survival was described by Kaplan-Meier test and analyzed by Cox regression.
RESULTS: A total of 105 individuals with DA were included, of whom 28 (26.7%) were COVID-19 survivors during the follow-up period. COVID-19 patients showed rapid AD progression compared with the control group (OR 4.76; 95% CI: 1.04-21.7; P = 0.044). Likewise, SARS-CoV-2 infection decreased patients' functionality, as indicated by the Katz index ( P =0.001). Functional impairment was observed in both mild and hospitalized cases of COVID-19. Hospitalized patients during COVID-19 demonstrated lower survival rates at the 5-year follow-up.
CONCLUSION: These findings suggest that SARS-CoV-2 infection may accelerate AD progression and reduce survival, particularly in cases requiring hospitalization. Future multicenter studies with large sample sizes are needed to confirm these findings.